Drug Insights

Is Daxxify approved by the FDA?

24 July 2024
2 min read

Daxxify, with the generic name daxibotulinumtoxinA-lanm, is an FDA-approved medication used for both cosmetic and therapeutic purposes. It belongs to the drug class of skeletal muscle relaxants and is administered as a lyophilized powder for injection.

Indications and Usage: Daxxify works as a longer-lasting botox injection due to its unique stabilizer (cell-penetrating peptide). It acts by inhibiting acetylcholine release and blocking neuromuscular transmission, thereby relaxing muscles. This mechanism helps reduce frown lines and alleviate symptoms of cervical dystonia, such as spasms and stiffness.

Dosage and Administration:

  • For Glabellar Lines: Typically administered as 0.1 mL (8 Units) per injection site into five specific points, totaling 40 Units.
  • For Cervical Dystonia: Dosage ranges from 125 Units to 250 Units, divided among affected muscles.

Side Effects: Common side effects of Daxxify include headaches, eyelid drooping, and temporary facial muscle weakness. Serious side effects may include heart problems, eye issues, allergic reactions, and potential spread of toxin effects to other body areas.

Warnings: Daxxify carries warnings about potential severe side effects like breathing difficulties, swallowing problems, and spread of toxin effects, which could affect distant muscles and cause symptoms of botulism.

Precautions: Before receiving Daxxify, patients should inform their healthcare providers about existing medical conditions, especially muscle or nerve disorders, prior botulinum toxin treatments, and current medications.

Conclusion: In summary, Daxxify is FDA approved for treating both glabellar lines and cervical dystonia in adults. Its unique formulation offers a longer duration of action compared to earlier botulinum toxins, making it a viable option for cosmetic enhancement and therapeutic relief.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Johnson & Johnson Seeks FDA Approval for SPRAVATO® as Standalone Treatment for Resistant Depression in Adults
Latest Hotspot
2 min read
Johnson & Johnson Seeks FDA Approval for SPRAVATO® as Standalone Treatment for Resistant Depression in Adults
24 July 2024
Johnson & Johnson is requesting U.S. FDA approval for SPRAVATO® (esketamine) as the sole treatment for adults with treatment-resistant depression.
Read →
Is Spesolimab approved by the FDA?
Drug Insights
2 min read
Is Spesolimab approved by the FDA?
24 July 2024
Spesolimab, marketed under the brand name Spevigo, received FDA approval for the treatment of generalized pustular psoriasis flares in adults.
Read →
Cytoki Pharma Reports Promising Phase 1 Results Indicating CK-0045 Could Enhance Cardiometabolic Health
Latest Hotspot
3 min read
Cytoki Pharma Reports Promising Phase 1 Results Indicating CK-0045 Could Enhance Cardiometabolic Health
24 July 2024
This study assessed the safety, tolerability, and pharmacokinetics of their leading lipidated IL-22 candidate, CK-0045.
Read →
Is Auvelity approved by the FDA?
Drug Insights
3 min read
Is Auvelity approved by the FDA?
24 July 2024
Auvelity, under its generic name bupropion and dextromethorphan, has been approved by the FDA for the treatment of major depressive disorder.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.